GLP-1 Receptor Agonists Confer No Increased Rates of IBD Exacerbation Among Patients With IBD

医学 兴奋剂 恶化 胰高血糖素样肽1受体 内科学 炎症性肠病 药方 克罗恩病 受体 胃肠病学 内分泌学 疾病 药理学
作者
Irving Levine,Shaina Sekhri,William Schreiber-Stainthorp,Brandon Locke,Olivia Delau,M. F. S. El-Hawary,Krutika Pandit,Xucong Meng,Jordan E. Axelrad
出处
期刊:Inflammatory Bowel Diseases [Oxford University Press]
被引量:1
标识
DOI:10.1093/ibd/izae250
摘要

Abstract Background In patients with inflammatory bowel disease (IBD), multimorbidity with obesity and type 2 diabetes is common and increasing. Glucagon-like peptide 1 (GLP-1) receptor agonists are increasingly being prescribed for patients with IBD, yet their impact on patients with IBD is largely unknown. We aimed to assess the impact of GLP-1 receptor agonists on the course of IBD. Methods We identified all IBD patients prescribed GLP-1 receptor agonists at a large academic healthcare network between 2009 and 2023. We analyzed demographics and IBD characteristics in the year pre- and post–GLP-1 receptor agonist prescription and matched them to non-IBD controls. Our primary outcome was IBD exacerbation in the year following GLP-1 receptor agonist initiation, measured as a composite of IBD-related hospitalization, corticosteroid prescription, medication escalation or changes, or IBD-related surgery. Secondary outcomes included change in metabolic risk factors. Results Overall, 224 patients met inclusion criteria. At GLP-1 receptor agonist initiation, the median age was 54 years, 63% were female, 77% were White, and median BMI was 33.2 kg/m2. Compared to the 12-month period prior to GLP-1 receptor agonist initiation, in the 12 months post–GLP-1 receptor agonist initiation, there was no change in rates of IBD exacerbation, IBD-related hospitalization, steroids prescription, medication escalation or changes, or IBD-related surgery. There was a significant decrease in BMI in the year following GLP-1 receptor agonist initiation (median BMI 33.5 vs 31.6 kg/m2, P < .01), with rates of decrease comparable to non-IBD matched controls. Conclusions In patients with IBD, GLP-1 receptor agonists are effective for weight loss and associated with few episodes of disease exacerbation.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
思源应助松松采纳,获得20
1秒前
共享精神应助酷炫葵阴采纳,获得10
3秒前
丝丢皮得完成签到 ,获得积分10
4秒前
5秒前
xfy完成签到,获得积分10
9秒前
阳炎完成签到,获得积分10
11秒前
行云流水完成签到,获得积分10
12秒前
13秒前
冷酷尔琴发布了新的文献求助10
17秒前
青水完成签到 ,获得积分10
21秒前
量子星尘发布了新的文献求助10
21秒前
21秒前
冷酷尔琴完成签到,获得积分10
21秒前
onevip完成签到,获得积分0
23秒前
小莫完成签到 ,获得积分10
25秒前
34秒前
theseus完成签到,获得积分10
35秒前
胡楠完成签到,获得积分10
37秒前
北国雪未消完成签到 ,获得积分10
38秒前
李振博完成签到 ,获得积分10
38秒前
48秒前
雪妮完成签到 ,获得积分10
51秒前
松松发布了新的文献求助20
54秒前
54秒前
iwsaml完成签到 ,获得积分10
54秒前
Caden完成签到 ,获得积分10
57秒前
xmhxpz完成签到,获得积分10
58秒前
was_3完成签到,获得积分10
58秒前
聪慧板凳完成签到,获得积分10
1分钟前
1分钟前
buerzi完成签到,获得积分10
1分钟前
魁梧的盼望完成签到 ,获得积分10
1分钟前
量子星尘发布了新的文献求助30
1分钟前
1分钟前
wzk完成签到,获得积分10
1分钟前
称心翠容完成签到,获得积分10
1分钟前
LaixS完成签到,获得积分10
1分钟前
尊敬代亦发布了新的文献求助10
1分钟前
要笑cc完成签到,获得积分10
1分钟前
青珊发布了新的文献求助10
1分钟前
高分求助中
【提示信息,请勿应助】关于scihub 10000
Les Mantodea de Guyane: Insecta, Polyneoptera [The Mantids of French Guiana] 3000
徐淮辽南地区新元古代叠层石及生物地层 3000
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
Handbook of Industrial Diamonds.Vol2 1100
Global Eyelash Assessment scale (GEA) 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 550
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 4038029
求助须知:如何正确求助?哪些是违规求助? 3575740
关于积分的说明 11373751
捐赠科研通 3305559
什么是DOI,文献DOI怎么找? 1819224
邀请新用户注册赠送积分活动 892652
科研通“疑难数据库(出版商)”最低求助积分说明 815022